52W $5.54 – $12.14
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.
Revenue breakdown: License And Collaboration Revenue (49.1%), Collaboration Revenue (49.1%), Product (1.8%).
10-K for FY2025 was filed on 2026-03-05. AI summary is not available yet.
Revenue by Segment